RESUMO
Uveitis is a potentially visually threatening disease accounting for 10% of vision loss in the developed world. The most common cause of vision loss in patients with uveitis has been shown to be macular edema (ME). The early detection and management of ME is critical to preserve vision in these patients. Optical coherence tomography (OCT) is a valuable tool in the management of many ocular diseases. The use of OCT has revolutionized the diagnosis and management of macular edema from a wide variety of ophthalmological diseases, including uveitis. In this review, we evaluate the role of OCT in the diagnosis and management of uveitic macular edema.
Assuntos
Edema Macular/diagnóstico , Tomografia de Coerência Óptica/métodos , Uveíte/diagnóstico , Humanos , Edema Macular/terapia , Uveíte/terapiaAssuntos
Bupropiona/efeitos adversos , Inibidores da Captação de Dopamina/efeitos adversos , Glaucoma de Ângulo Fechado/induzido quimicamente , Doenças da Úvea/induzido quimicamente , Adulto , Transtorno Depressivo/tratamento farmacológico , Feminino , Glaucoma de Ângulo Fechado/diagnóstico por imagem , Glaucoma de Ângulo Fechado/tratamento farmacológico , Humanos , Pressão Intraocular/efeitos dos fármacos , Microscopia Acústica , Doenças da Úvea/diagnóstico por imagem , Doenças da Úvea/tratamento farmacológico , Transtornos da Visão/induzido quimicamente , Transtornos da Visão/diagnóstico , Acuidade VisualRESUMO
Uveitis can be a sight-threatening eye disease with significant morbidity. Corticosteroids remain the mainstay of treatment of uveitis and provide an effective treatment against ocular inflammation. However, the various modes available for corticosteroid drug delivery can carry significant ocular and systemic side effects which can limit their use in the treatment of uveitis. In an effort to avoid the damage to ocular structures that can ensue with recurrent episodes of ocular inflammation, the side effects associated with systemic steroids, and the need for repeated administration of both topical and locally injected corticosteroids, sustained-release intraocular corticosteroid implants have been developed. The dexamethasone (DEX) drug delivery system (Ozurdex(®); Allergan Inc, Irvine, CA), is a biodegradable intravitreal implant. This implant has been shown to be effective in the treatment of macular edema and noninfectious posterior uveitis and has been approved by the FDA for these entities. This review will highlight the current methods available for corticosteroid delivery to the eye with a particular emphasis on the DEX intravitreal implant and the evidence currently available for its use in noninfectious uveitis.
